Expression of hepcidin and other iron-regulatory genes in human hepatocellular carcinoma and its clinical implications.
about
Ligand-based targeted therapy: a novel strategy for hepatocellular carcinomaAn efficient targeted drug delivery through apotransferrin loaded nanoparticlesEfficacy, safety and anticancer activity of protein nanoparticle-based delivery of doxorubicin through intravenous administration in ratsGlobal gene profiling of spontaneous hepatocellular carcinoma in B6C3F1 mice: similarities in the molecular landscape with human liver cancerClodronate-superparamagnetic iron oxide-containing liposomes attenuate renal injury in rats with severe acute pancreatitis.The iron chelator Dp44mT inhibits hepatocellular carcinoma metastasis via N-Myc downstream-regulated gene 2 (NDRG2)/gp130/STAT3 pathway.Chronic administration of 2-acetylaminofluorene alters the cellular iron metabolism in rat liver.Analysis of hepcidin expression: in situ hybridization and quantitative polymerase chain reaction from paraffin sections.Preparation and in vitro studies of MRI-specific superparamagnetic iron oxide antiGPC3 probe for hepatocellular carcinoma.Preoperative mean corpuscular hemoglobin affecting long-term outcomes of hepatectomized patients with hepatocellular carcinoma.MicroRNA-152-mediated dysregulation of hepatic transferrin receptor 1 in liver carcinogenesis.Iron depletion enhances the effect of sorafenib in hepatocarcinomaCorrelation of serum hepcidin levels with disease progression in hepatitis B virus-related disease assessed by nanopore film based assayActive radar guides missile to its target: receptor-based targeted treatment of hepatocellular carcinoma by nanoparticulate systems.Downregulation of hemojuvelin prevents inhibitory effects of bone morphogenetic proteins on iron metabolism in hepatocellular carcinoma.Quantitative proteomic analysis in HCV-induced HCC reveals sets of proteins with potential significance for racial disparity.Efficacy of iron chelator deferoxamine for hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma patients refractory to current treatments.Hepcidin and DNA promoter methylation in hepatocellular carcinoma.Differential regulation of hepcidin in cancer and non-cancer tissues and its clinical implications.Anemia in lymphoma: interleukin-6, hepcidin and erythropoietin.
P2860
Q28068437-B2572B22-7A62-42B6-BD1E-1685BA4D541DQ28476276-0EA794AF-4CAF-4255-BDA7-CF4059362C58Q28484539-7F98E381-06A0-44F3-956C-308073BF6DE5Q28829385-4F811A55-E438-4B78-965D-AA327D04BF2CQ33979101-106D3172-94C3-4BBF-80A1-9EC7EA20777EQ34483637-9ACEEA87-6186-40ED-B480-98591D0B03C1Q35231099-A8A1FDEB-2709-4799-AD61-3794B98EA267Q36121246-FEB2E8CA-6D5D-4F26-A018-BCF0FB0D87C8Q36202879-53E1C59A-13B8-4D38-BF64-62CCB4CE077BQ36523881-075E1E53-6BC6-44E7-BDEC-987E416491EBQ36738803-02EE7B5A-1ADF-4ABD-943A-66554751E628Q37187753-357751FE-251B-4A7E-B09E-99D9DF2E21F5Q37303512-B686909B-7095-4953-B123-259FC6EAFDDCQ38271422-76C07E60-64D3-4C26-A2BA-5BAA42B70A11Q38332451-64289077-38A9-4F01-9EC1-0DB8409D99FCQ38482765-B176B846-FA48-408C-AF17-05B90E016664Q38982079-CA378030-EE20-45FD-A39F-BD1E598C50DDQ48128368-B781BA4E-94C7-4908-9D8B-67FB52552551Q49389245-C24A4E62-EF94-427C-8467-6429672A03A4Q50955871-67192A7E-0966-4A1E-8FD5-DA8FF6D680FE
P2860
Expression of hepcidin and other iron-regulatory genes in human hepatocellular carcinoma and its clinical implications.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Expression of hepcidin and oth ...... and its clinical implications.
@en
Expression of hepcidin and oth ...... and its clinical implications.
@nl
type
label
Expression of hepcidin and oth ...... and its clinical implications.
@en
Expression of hepcidin and oth ...... and its clinical implications.
@nl
prefLabel
Expression of hepcidin and oth ...... and its clinical implications.
@en
Expression of hepcidin and oth ...... and its clinical implications.
@nl
P2093
P2860
P1476
Expression of hepcidin and oth ...... and its clinical implications
@en
P2093
Hsi-Huang Tseng
Hsin-Su Yu
Jan-Gowth Chang
Kun-Tu Yeh
Yao-Li Chen
P2860
P2888
P304
P356
10.1007/S00432-009-0585-5
P577
2009-04-23T00:00:00Z